Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2025)
Whitehawk Therapeutics (WHWK) reported Cash from Financing Activities of $25000.0 for Q4 2025, down 52.83% year-over-year from $53000.0 in Q4 2024, and up 102.94% quarter-over-quarter from -$850000.0 in Q2 2025.
Whitehawk Therapeutics (WHWK) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 12 years of Cash from Financing Activities data on file, last reported at $25000.0 in Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at $25000.0, down 52.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$825000.0 (down 100.87% YoY), and the FY2025 annual result was $94.4 million, up 72496.92% from the prior year.
- Cash from Financing Activities grew to $25000.0 in Q4 2025 per WHWK's latest filing, from -$850000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $141.7 million in Q3 2021 and troughed at -$850000.0 in Q2 2025.
- A 5-year average of $17.2 million and a median of $61639.5 in 2021 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 952110.0% in 2025 and fell as far as 1077.01% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $88000.0 in 2021, then slumped by 221.59% to -$107000.0 in 2022, then jumped by 174.77% to $80000.0 in 2023, then sank by 33.75% to $53000.0 in 2024, then slumped by 52.83% to $25000.0 in 2025.
- Business Quant data shows WHWK's Cash from Financing Activities at $25000.0 in Q4 2025, -$850000.0 in Q2 2025, and $95.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Jun 30, 2025 | -850,000.00 |
| Mar 31, 2025 | 95.20 Mn |
| Mar 31, 2025 | 95.20 Mn |
| Dec 31, 2024 | 53,000.00 |
| Dec 31, 2024 | 53,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | 313,000.00 |
| Jun 30, 2023 | 313,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |